1 result for "Nanjing Legend Biotech Co., Ltd."
Add this URL to any RSS reader. Updated daily.
Nanjing Legend Biotech CAR-T Patent, GPC2 Cancer Immunotherapy
The USPTO granted Patent US12606635B2 to Nanjing Legend Biotech Co., Ltd. covering GPC2-specific antibodies, antigen binding fragments, and chimeric antigen receptor (CAR) constructs for cancer immunotherapy. The patent encompasses T cells engineered with the disclosed CAR constructs. The application (No. 17910608) was filed March 12, 2021, and contains 19 claims.
Routine
Rule
Intellectual Property
Get alerts for "Nanjing Legend Biotech Co., Ltd."
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Browse Categories
Agriculture & Food Safety
73
AI Regulation
3
Banking & Finance
414
Consumer Protection
89
Courts & Legal
411
Data Privacy & Cybersecurity
90
Defense & National Security
53
Education
55
Energy
100
Environment
152
Gaming
2
Government & Legislation
431
Healthcare
15
Healthcare & Life Sciences
375
Immigration
10
Insurance
76
Labor & Employment
138
Pharma & Drug Safety
21
Professional Licensing
8
Real Estate & Housing
78
Securities & Markets
154
Tax
78
Telecom & Technology
47
Trade & Sanctions
141
Transportation
91
Get alerts for "Nanjing Legend Biotech Co., Ltd."
We'll email you when new changes match "Nanjing Legend Biotech Co., Ltd.".
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.
You're subscribed!